BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Arexis AB Enters Into Collaboration With CMC Biopharmaceuticals A/S For The Production Of BSSL For Clinical Trials


10/19/2005 5:12:57 PM

GOTHENBURG, SWEDEN 7 March 2005 The drug development company Arexis AB announced today that it has entered into a collaboration agreement with the Danish company CMC Biopharmaceuticals on the production of recombinant human BSSL for the upcoming cystic fibrosis and preterm infant clinical trials.

The collaboration represents an important step in the preparations for the BSSL (bile salt-stimulated lipase) clinical trials in cystic fibrosis patients with fat malabsorption and preterm infants. Under the collaboration agreement, Copenhagen-based CMC Biopharmaceuticals, a contract development and manufacturing organization specialized in GMP manufacturing (good manufacturing practice, required for substances in clinical development), will provide Arexis with all recombinant human BSSL for the trials.

With its impressive qualities in GMP manufacturing, CMC represents an ideal partner for the timely and reliable delivery of high-quality BSSL for our clinical trials,” says Lennart Hansson, CEO of Arexis.

Recombinant BSSL is an exciting new biopharmaceutical, and we look forward to starting production in a close and fruitful collaboration with Arexis,” says Mads Laustsen, CEO of CMC Biopharmaceuticals.

The key function of BSSL is to degrade a large spectrum of lipids in food. Arexis’ BSSL program consists of two projects where its patented human recombinant enzyme is used to target fat malabsorption in cystic fibrosis patients and preterm infants. Following the recent successful cystic fibrosis phase II clinical trials which proved the concept, Arexis now plans a dose-finding study followed by a clinical phase III trial. Arexis also plans clinical phase II preterm infant efficacy studies. As a future therapeutic option, BSSL is perhaps the most promising new entry of options to improve fat malabsorption currently in development.

The cystic fibrosis project recently received orphan drug status in the EU. The preterm infant studies will be part of the EARNEST EU-funded program, and orphan drug designations will be applied for in the EU and US.

CMC Biopharmaceuticals will produce BSSL in a mammalian cell bioreactor, with the first batch reserved for the dose-finding cystic fibrosis study and the initial preterm infant clinical phase II studies, and the second batch to be used in the clinical phase III cystic fibrosis trial. Mammalian cell culture production systems are very well established for producing recombinant therapeutic proteins. CMC Biopharmaceuticals will base its production on one of Arexis’ proprietary cell lines.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES